| 1.85 0 (0%) | 01-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.34 | 1-year : | 2.74 |
| Resists | First : | 2 | Second : | 2.34 |
| Pivot price | 1.57  |
|||
| Supports | First : | 1.49 | Second : | 1.16 |
| MAs | MA(5) : | 1.75 |
MA(20) : | 1.58 |
| MA(100) : | 1.58 |
MA(250) : | 1.74  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 80.9 |
D(3) : | 71.9 |
| RSI | RSI(14): 65.2 | |||
| 52-week | High : | 2.75 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ANL ] has closed below upper band by 6.5%. Bollinger Bands are 62.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.91 - 1.92 | 1.92 - 1.93 |
| Low: | 1.76 - 1.77 | 1.77 - 1.78 |
| Close: | 1.83 - 1.85 | 1.85 - 1.86 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Tue, 20 Jan 2026
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Mon, 29 Dec 2025
ANL: Stock Soars Amidst Market Speculations - timothysykes.com
Mon, 29 Dec 2025
Adlai Nortye Licenses Pan-RAS Inhibitor AN9025 to ASK Pharm for Greater China - TipRanks
Mon, 29 Dec 2025
ANL Stocks Rocket: Time to Jump In? - timothysykes.com
Mon, 29 Dec 2025
Deal worth up to $230M grants China rights to new RAS cancer drug - Stock Titan
Mon, 29 Dec 2025
Is It Too Late to Buy Adlai Nortye? - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 31 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 8.5 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 321 (K) |
| Shares Short P.Month | 9 (K) |
| EPS | -1.14 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.9 % |
| Return on Equity (ttm) | -139 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.35 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -1.63 |
| PEG Ratio | 0 |
| Price to Book value | 8.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|